Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2012-09-28 Investor Presentation
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
FWP Filing
Investor Presentation Classification · 95% confidence The document is a detailed presentation about a pharmaceutical product, ARIKACE, including clinical trial data, development plans, market opportunity, and scientific rationale. It contains forward-looking statements, clinical study descriptions, and detailed information about the drug's development stages and market potential. The document is structured as a presentation aimed at investors or stakeholders, focusing on financial position, clinical trial progress, and business strategy. It does not contain formal financial statements, audit opinions, or regulatory filings such as 10-K or 10-Q reports. It is not a transcript of a call, nor an announcement of voting results or management changes. The content aligns with an Investor Presentation (IP) as it provides detailed information on financials, strategy, and market position related to the product and company.
2012-09-28 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 28, 2012. It reports the entry into a material definitive agreement involving the sale of common stock and the expected gross proceeds from this offering. The document includes references to a securities purchase agreement, a prospectus supplement, and a press release about the offering. The content focuses on financing activities, specifically the issuance of shares and capital raising. There are no financial statements or detailed financial results presented, nor is this an announcement of voting results, management changes, or legal proceedings. The primary subject is the company's capital raising through a securities offering, which fits the Capital/Financing Update category. The document length is 4028 characters, which is sufficient to contain substantive information about the financing event rather than just an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-09-28 English
4 Filing
Director's Dealing
2012-09-12 English
3 Filing
Director's Dealing
2012-09-12 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 10, 2012, reporting the departure of the former CEO and appointment of a new CEO, along with related employment agreements and severance arrangements. The key content is about changes in the company's board and senior management, including appointment and resignation of officers and directors. There are no financial statements or detailed financial performance data included. The document fits the description of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length (9348 characters) is sufficient to contain substantive information, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is MANG with high confidence.
2012-09-11 English
8-K Filing
Call Transcript Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2012. It specifically states that it includes a transcript of a conference call held on that date to discuss financial results for the three and six months ended June 30, 2012. The transcript is attached as Exhibit 99.1. The content and context clearly indicate this is a full text transcript of a company conference call, which matches the definition of a Call Transcript (CT). The document length is 4505 characters, which is consistent with a transcript or a report containing substantive content rather than a brief announcement. Therefore, the appropriate classification is Call Transcript (CT).
2012-08-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.